Fig. 2From: Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-upLong-term survival (10-year follow-up). There was no significant difference among three groups in long-term survival. (log-rank test, p = 0.844). (Group T = tranexamic acid group; Group U = ulinastatin group; Group C = placebo group)Back to article page